Dr Susan F Neshin, MD | |
1200 Memorial Dr, Asbury Park, NJ 07712-5008 | |
(732) 988-8877 | |
(732) 988-2572 |
Full Name | Dr Susan F Neshin |
---|---|
Gender | Male |
Speciality | Psychiatry & Neurology - Addiction Medicine |
Location | 1200 Memorial Dr, Asbury Park, New Jersey |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821203316 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084A0401X | Psychiatry & Neurology - Addiction Medicine | MA04170100 (New Jersey) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Susan F Neshin, MD 685 Neptune Blvd, Neptune, NJ 07753-4118 Ph: (732) 988-8877 | Dr Susan F Neshin, MD 1200 Memorial Dr, Asbury Park, NJ 07712-5008 Ph: (732) 988-8877 |
News Archive
The University of Maryland Medical Center is now offering a simple genetic test to patients who receive heart stents to determine whether they have a genetic deficiency that affects how they respond to a common drug to prevent blood clots.
Some children and adolescents think that they will have an accident if they do not count all the lampposts on their way to school. Or cannot leave the house unless they have washed their hands precisely twenty-five times.
Teva Pharmaceutical Industries Ltd. announced today U.S. Food and Drug Administration (FDA) approval of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. Shipment is expected to commence on July 1, 2010, as per the terms of the 2006 agreement with Wyeth.
A scientist on the Florida campus of The Scripps Research Institute has won a prestigious New Innovator Award from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH).
Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.
› Verified 4 days ago